Product image of Mekinist (Trametinib) supplied by GNH India

Mekinist

Active Ingredient:
Trametinib
Origin:
EU

Mekinist (Trametinib)

Trametinib, the active ingredient in Mekinist, is a MEK inhibitor presented as a tablet for oral use. It targets cancers that harbor BRAF V600E or V600K mutations, including melanoma, non‑small cell lung cancer, anaplastic thyroid cancer and colorectal cancer, and is prescribed for adult patients under specialist supervision.

GNH India supplies Mekinist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing and ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mekinist (trametinib) is indicated for malignancies driven by the MAPK pathway, particularly those with BRAF V600 mutations.

  • BRAF V600E/K mutation‑positive melanoma: improves progression‑free survival in adult patients.
  • Non‑small cell lung cancer with KRAS G12C mutation (in combination therapy): contributes to disease control.
  • Anaplastic thyroid cancer with BRAF V600E mutation: offers a targeted treatment option.
  • Colorectal cancer with BRAF V600E mutation (in combination): enhances therapeutic response.

How It Works

  • Trametinib selectively inhibits the serine/threonine kinases MEK1 and MEK2, blocking downstream MAPK/ERK signaling. By preventing phosphorylation of ERK, the drug reduces tumor cell proliferation and survival in cancers dependent on this pathway, particularly those harboring BRAF V600 mutations.

Side Effects

Adverse reactions to trametinib may vary in frequency and severity.

Common Side Effects

  • Diarrhea
  • Rash or acneiform dermatitis
  • Nausea
  • Fatigue
  • Peripheral edema
  • Stomatitis

Serious or Rare Side Effects

  • Interstitial lung disease or pneumonitis
  • Decreased left ventricular ejection fraction or cardiomyopathy
  • Severe hepatic injury (elevated transaminases)
  • Ocular toxicity such as retinal vein occlusion
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis
  • Severe hemorrhage or bleeding events

Precautions & Warnings

When prescribing trametinib, clinicians should consider several safety measures.

  • Dose adjustments: required for patients with moderate to severe hepatic impairment.
  • Cardiac monitoring: obtain baseline and periodic left ventricular ejection fraction assessments.
  • Dermatologic evaluation: monitor for severe rash, skin ulceration, or other cutaneous reactions.
  • Ophthalmologic assessment: perform baseline eye exam and periodic monitoring for retinal disorders.
  • Pregnancy and lactation: avoid use due to unknown safety; discuss risks with a specialist.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Trametinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce trametinib exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase trametinib plasma levels.
  • Co‑administration with other MEK inhibitors: heightened risk of overlapping toxicities.
  • QT‑prolonging agents: increased potential for cardiac arrhythmias.
  • Anticoagulants combined with anti‑angiogenic agents: elevated bleeding risk.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise trametinib concentrations.
  • Acid‑reducing agents (e.g., proton‑pump inhibitors): could affect drug absorption.
  • Systemic corticosteroids: may mask early skin toxicity.
  • Live vaccines: should be avoided during treatment.
  • Herbal supplements such as St. John’s wort: may alter metabolic clearance.

Frequently Asked Questions

Mekinist, whose active ingredient is trametinib, is approved for adult patients with BRAF V600E/K mutation‑positive melanoma, certain non‑small cell lung cancers, anaplastic thyroid cancer, and colorectal cancer that carry the same mutation, either as monotherapy or in combination with other targeted agents.

Trametinib blocks the activity of MEK1 and MEK2 kinases, which are key components of the MAPK/ERK signaling cascade. By inhibiting this pathway, the drug reduces tumor cell proliferation and survival in cancers that rely on MAPK signaling, especially those with BRAF V600 mutations.

The prescribed dose of Mekinist is determined by the treating oncologist based on the specific indication, patient characteristics, and any concomitant therapies. Dosage adjustments may be required for hepatic impairment or drug‑drug interactions, and the prescriber will provide detailed instructions.

The safety of trametinib in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and a specialist should be consulted for risk‑benefit assessment.

To request Mekinist, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mekinist (trametinib) is a selective MEK1/2 inhibitor with a well‑characterised safety profile. Compared with other agents in the same class, such as cobimetinib, trametinib has a similar efficacy in BRAF‑mutated melanoma but may differ in the incidence of specific adverse events like rash or ocular toxicity, influencing clinician choice based on patient tolerance.

Mekinist tablets should be stored at temperatures below 25 °C, in the original packaging to protect them from moisture and light. Do not store in areas with high humidity or direct sunlight, and keep out of reach of children.

Mekinist is taken orally as a tablet, usually once daily, with or without food, as directed by the prescribing physician. Patients should swallow the tablet whole with water and follow any specific instructions regarding timing relative to other medications.

Serious risks include interstitial lung disease or pneumonitis, decreased left ventricular ejection fraction leading to cardiomyopathy, severe hepatic injury, ocular events such as retinal vein occlusion, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for these events.

Mekinist is contraindicated in patients with known hypersensitivity to trametinib or any of its excipients. It should also be avoided in individuals receiving strong CYP3A4 inducers that would markedly lower drug exposure, and in patients with uncontrolled cardiac disease or severe hepatic impairment without dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Trametinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT